• Tag results for Dr reddy

Dr Reddy's to market aspirin, anti-coagulant drug in US

Dr Reddys Laboratories Ltd Monday announced it has received the approval of the US Food and Drug Administration to market aspirin and dipyridamole capsules in the USA.

published on : 15th October 2018

Dr Reddy's announces sale of its API manufacturing unit in Jeedimetla

This divestiture is being done by way of slump sale (as a going concern) and includes all related fixed assets (land and building), current assets, current liabilities, and its employees.

published on : 15th October 2018

Dr Reddy's Labs recalls 35,000 tubes of skin infection cream from US

The recall is on account of "failed stability specifications - an out of specification result was observed for the test parameter: composition of Nystatin during stability testing," it added.

published on : 14th October 2018

Dr Reddy's recalls around 70,000 vials of Zoledronic acid injection from US

The vials were manufactured by Gland Pharma for Dr Reddy's Laboratories, the Enforcement Report said.

published on : 3rd October 2018

Dr Reddy's launches Hervycta to treat cancer in India 

Hervycta (Trastuzumab), a biosimilar of Roche's Herceptin in India, is used for treatment of early breast cancer, metastatic breast cancer and metastatic gastric cancer).

published on : 26th July 2018

Dr Reddy's to appeal US District Court's decision on sale of generic Buprenorphine and Suboxone film

The company intends to appeal the decision made by the US District Court of New Jersey in a preliminary injunction hearing with respect to further sales and commercialisation of its product in the US.

published on : 14th July 2018

Dr Reddy's launches anti-epilepsy drug in US market

The drug has been approved by the US Food and Drug Administration (USFDA).

published on : 19th June 2018

Dr Reddy's Laboratories launches Levetiracetam in Sodium Chloride Injection in the US Market

The Levetiracetam in Sodium Chloride Injection brand and generic had US sales of approximately USD 37 million MAT for the most recent twelve months ending in April 2018 according to IMS Health.

published on : 19th June 2018

Dr Reddy's gets EIR from USFDA for Srikakulam plant

The company, without mentioning the contents of the EIR, said the USFDA has maintained OAI status at its API manufacturing plant in Srikakulam.

published on : 26th February 2018

Dr Reddy's Q3 profit tumbles, hit by U.S. pricing pressure

Indian generic drugmaker Dr Reddy's Laboratories Ltd posted a 38.5 percent slump in quarterly net profit as sales declined due to pricing pressure in the United States, its biggest market.

published on : 25th January 2018

Rupee rises by 14 paise against dollar; Sensex up 101 points

Most Asian markets were trading higher as solid economic data from the United States and Germany reinforced investors' optimism.

published on : 4th January 2018

Dr Reddy's Labs shares extend losses, down 3 per cent

Meanwhile, BSE earlier in the day sought clarification from the company on reports that Dr Reddy's shares fell on the buzz of issues raised in EIR for Duvvada plant.

published on : 3rd January 2018

US bans Indian drugmaker Divi's factory, shares hit three-year low

The FDA also found violations of manufacturing standards at Dr Reddy's Laboratories Ltd's drug plant, also in Vizag, during an inspection.

published on : 22nd March 2017

Dr Reddy's, Aurobindo recall drugs from US market

A notification by the FDA said recalls are voluntarily initiated by the two companies.

published on : 15th February 2017